Rigel Pharmaceuticals (RIGL) EPS (Weighted Average and Diluted) Growth (1y) (2011 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -82.39% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -97.49% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -79.34% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 61.45% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -7.15% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,178.57% |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | -30.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.16% |
| Dec 31, 2025 | 1,640.74% |
| Sep 30, 2025 | 108.57% |
| Jun 30, 2025 | 5,566.67% |
| Mar 31, 2025 | 234.04% |
| Dec 31, 2024 | 1,520.00% |
| Sep 30, 2024 | 312.12% |
| Jun 30, 2024 | 84.21% |
| Mar 31, 2024 | -487.50% |
| Dec 31, 2023 | 101.62% |
| Sep 30, 2023 | -200.00% |
| Jun 30, 2023 | -375.00% |
| Mar 31, 2023 | 50.00% |
| Dec 31, 2022 | -2,107.14% |
| Sep 30, 2022 | 8.33% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | -172.73% |
| Dec 31, 2021 | -16.67% |
| Sep 30, 2021 | -50.00% |
| Jun 30, 2021 | 20.00% |
| Mar 31, 2021 | 69.23% |
| Dec 31, 2020 | -16.79% |
| Jun 30, 2020 | 18.87% |
| Mar 31, 2020 | 218.18% |
| Dec 31, 2012 | 21.62% |
| Sep 30, 2012 | -44.00% |
| Jun 30, 2012 | 5.41% |
| Mar 31, 2012 | 18.38% |
| Dec 31, 2011 | -12.12% |
| Sep 30, 2011 | -126.04% |
| Jun 30, 2011 | -172.55% |